Reteplase Fc-fusions produced in N. benthamiana are able to dissolve blood clots ex vivo.
Thrombolytic and fibrinolytic therapies are effective treatments to dissolve blood clots in stroke therapy. Thrombolytic drugs activate plasminogen to its cleaved form plasmin, a proteolytic enzyme that breaks the crosslinks between fibrin molecules. The FDA-approved human tissue plasminogen activat...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2021-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0260796&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850162776619614208 |
|---|---|
| author | Shiva Izadi Mokhtar Jalali Javaran Sajad Rashidi Monfared Alexandra Castilho |
| author_facet | Shiva Izadi Mokhtar Jalali Javaran Sajad Rashidi Monfared Alexandra Castilho |
| author_sort | Shiva Izadi |
| collection | DOAJ |
| description | Thrombolytic and fibrinolytic therapies are effective treatments to dissolve blood clots in stroke therapy. Thrombolytic drugs activate plasminogen to its cleaved form plasmin, a proteolytic enzyme that breaks the crosslinks between fibrin molecules. The FDA-approved human tissue plasminogen activator Reteplase (rPA) is a non-glycosylated protein produced in E. coli. rPA is a deletion mutant of the wild-type Alteplase that benefits from an extended plasma half-life, reduced fibrin specificity and the ability to better penetrate into blood clots. Different methods have been proposed to improve the production of rPA. Here we show for the first time the transient expression in Nicotiana benthamiana of rPA fused to the immunoglobulin fragment crystallizable (Fc) domain on an IgG1, a strategy commonly used to improve the stability of therapeutic proteins. Despite our success on the expression and purification of dimeric rPA-Fc fusions, protein instability results in high amounts of Fc-derived degradation products. We hypothesize that the "Y"- shape of dimeric Fc fusions cause steric hindrance between protein domains and leads to physical instability. Indeed, mutations of critical residues in the Fc dimerization interface allowed the expression of fully stable rPA monomeric Fc-fusions. The ability of rPA-Fc to convert plasminogen into plasmin was demonstrated by plasminogen zymography and clot lysis assay shows that rPA-Fc is able to dissolve blood clots ex vivo. Finally, we addressed concerns with the plant-specific glycosylation by modulating rPA-Fc glycosylation towards serum-like structures including α2,6-sialylated and α1,6-core fucosylated N-glycans completely devoid of plant core fucose and xylose residues. |
| format | Article |
| id | doaj-art-5ce5eeb1ef3f4c788f4e2492eb9d9abb |
| institution | OA Journals |
| issn | 1932-6203 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-5ce5eeb1ef3f4c788f4e2492eb9d9abb2025-08-20T02:22:28ZengPublic Library of Science (PLoS)PLoS ONE1932-62032021-01-011611e026079610.1371/journal.pone.0260796Reteplase Fc-fusions produced in N. benthamiana are able to dissolve blood clots ex vivo.Shiva IzadiMokhtar Jalali JavaranSajad Rashidi MonfaredAlexandra CastilhoThrombolytic and fibrinolytic therapies are effective treatments to dissolve blood clots in stroke therapy. Thrombolytic drugs activate plasminogen to its cleaved form plasmin, a proteolytic enzyme that breaks the crosslinks between fibrin molecules. The FDA-approved human tissue plasminogen activator Reteplase (rPA) is a non-glycosylated protein produced in E. coli. rPA is a deletion mutant of the wild-type Alteplase that benefits from an extended plasma half-life, reduced fibrin specificity and the ability to better penetrate into blood clots. Different methods have been proposed to improve the production of rPA. Here we show for the first time the transient expression in Nicotiana benthamiana of rPA fused to the immunoglobulin fragment crystallizable (Fc) domain on an IgG1, a strategy commonly used to improve the stability of therapeutic proteins. Despite our success on the expression and purification of dimeric rPA-Fc fusions, protein instability results in high amounts of Fc-derived degradation products. We hypothesize that the "Y"- shape of dimeric Fc fusions cause steric hindrance between protein domains and leads to physical instability. Indeed, mutations of critical residues in the Fc dimerization interface allowed the expression of fully stable rPA monomeric Fc-fusions. The ability of rPA-Fc to convert plasminogen into plasmin was demonstrated by plasminogen zymography and clot lysis assay shows that rPA-Fc is able to dissolve blood clots ex vivo. Finally, we addressed concerns with the plant-specific glycosylation by modulating rPA-Fc glycosylation towards serum-like structures including α2,6-sialylated and α1,6-core fucosylated N-glycans completely devoid of plant core fucose and xylose residues.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0260796&type=printable |
| spellingShingle | Shiva Izadi Mokhtar Jalali Javaran Sajad Rashidi Monfared Alexandra Castilho Reteplase Fc-fusions produced in N. benthamiana are able to dissolve blood clots ex vivo. PLoS ONE |
| title | Reteplase Fc-fusions produced in N. benthamiana are able to dissolve blood clots ex vivo. |
| title_full | Reteplase Fc-fusions produced in N. benthamiana are able to dissolve blood clots ex vivo. |
| title_fullStr | Reteplase Fc-fusions produced in N. benthamiana are able to dissolve blood clots ex vivo. |
| title_full_unstemmed | Reteplase Fc-fusions produced in N. benthamiana are able to dissolve blood clots ex vivo. |
| title_short | Reteplase Fc-fusions produced in N. benthamiana are able to dissolve blood clots ex vivo. |
| title_sort | reteplase fc fusions produced in n benthamiana are able to dissolve blood clots ex vivo |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0260796&type=printable |
| work_keys_str_mv | AT shivaizadi reteplasefcfusionsproducedinnbenthamianaareabletodissolvebloodclotsexvivo AT mokhtarjalalijavaran reteplasefcfusionsproducedinnbenthamianaareabletodissolvebloodclotsexvivo AT sajadrashidimonfared reteplasefcfusionsproducedinnbenthamianaareabletodissolvebloodclotsexvivo AT alexandracastilho reteplasefcfusionsproducedinnbenthamianaareabletodissolvebloodclotsexvivo |